pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLCpulmo-92Research ArticleКЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯCLINICAL PHARMACOLOGYВоспроизведенные ингаляционные лекарственные средства: как оценить их свойства?Generic inhaled drugs: how to evaluate their properties?ЗыряновС. К.ZyryanovS. K.

д. м. н., проф. кафедры клинической фармакологии 

117437, Москва, ул. Островитянова, 1. Тел.: (499) 261-25-90.

serguei-kensarin@hotbox.ruАйсановЗ. Р.AisanovZ. R.

д. м. н., проф., зав. отделом клинической физиологии и клинических исследований 

105077, Москва, ул. 11-я Парковая, 32, корп. 4. Тел.: (495) 965-34-66.

aisanov@mail.ruГБОУ ВПО "Российский национальный исследовательский медицинский университет им. Н.И.Пирогова"Russian FederationФГУ "НИИ пульмонологии" ФМБА РоссииRussian Federation20122806201203115118Copyright © Зырянов С.К., Айсанов З.Р., 20122012Зырянов С.К., Айсанов З.Р.Zyryanov S.K., Aisanov Z.R.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/92

Воспроизведенные ингаляционные лекарственные средства: как оценить их свойства?

Generic inhaled drugs: how to evaluate their properties?

генерикфармацевтическая эквивалентностьgenericpharmaceutical equivalenceReferencesFDA. Orange book: Approved drug products with therapeutic equivalence evaluations. 30th ed.; 2010.FDA. Orange book: Approved drug products with therapeutic equivalence evaluations. 30th ed.; 2010.Белоусов Ю.Б., Зырянов С.К. Дженерики и бренды: pro et contra. Качеств. клини. практ. 2003; 2: 95–100.Белоусов Ю.Б., Зырянов С.К. Дженерики и бренды: pro et contra. Качеств. клини. практ. 2003; 2: 95–100.Daley'Yates P.T., Parkins D.A. Establishing bioequivalence for inhaled drug, weighing the evidence. Expert. Opin. Drug Deliv. 2011; 1: 112.Daley'Yates P.T., Parkins D.A. Establishing bioequivalence for inhaled drug, weighing the evidence. Expert. Opin. Drug Deliv. 2011; 1: 112.European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents Doc. Ref. CPMP/ EWP/4151/00 Rev. 1. Jan. 2009. London; 2009.European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents Doc. Ref. CPMP/ EWP/4151/00 Rev. 1. Jan. 2009. London; 2009.Lawrence M., Wolfe J., Webb D.R. et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am. J. Respir. Crit. Care Med. 1997; 156: 744–751.Lawrence M., Wolfe J., Webb D.R. et al. Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am. J. Respir. Crit. Care Med. 1997; 156: 744–751.Clearie K.I., Williamson P.A., Vaidyanathan S. et al. Systemic bioavailability of hydrofluoroalkane formulation of fluticasone / salmeterol in healthy volunteers via pMDI alone and spacer. Br. J. Clin. Pharmacol. 2010; 69: 637–644.Clearie K.I., Williamson P.A., Vaidyanathan S. et al. Systemic bioavailability of hydrofluoroalkane formulation of fluticasone / salmeterol in healthy volunteers via pMDI alone and spacer. Br. J. Clin. Pharmacol. 2010; 69: 637–644.Информационное письмо-обращение экспертов Российского респираторного общества к врачам первичного звена и специалистам в области пульмонологии. Пульмонология 2011; 6; 119.Информационное письмо-обращение экспертов Российского респираторного общества к врачам первичного звена и специалистам в области пульмонологии. Пульмонология 2011; 6; 119.

The authors declare that there are no conflicts of interest present.